Haley Emery, Luke Natalie, Korman Howard, Rao Ganesh Srinvas, Baunoch David, Chen Xiaofei, Havrilla Jim, Mathur Mohit
Department of Clinical Research, Pathnostics, Irvine, CA 92618, USA.
School of Medicine, Wayne State University, Detroit, MI 48201, USA.
J Clin Med. 2024 Dec 7;13(23):7453. doi: 10.3390/jcm13237453.
We aimed to compare the prescribing behavior and clinical experience of urology providers when using the combined multiplex polymerase chain reaction (M-PCR)/Pooled Antibiotic Susceptibility Testing (P-AST) diagnostic test versus the standard urine culture (SUC) in the same set of patients previously reported to have improved clinical outcomes with M-PCR/P-AST. We conducted a multi-centered, prospective, observational study (clinical trial registration: NCT05091931) with Western Institutional Review Board (IRB) approval (20214705). Adult subjects were split between the M-PCR/P-AST ( = 250) and SUC arms ( = 135). Treatment details were determined by clinician and subject surveys. Differences in prescribed antibiotics were compared using the Chi-square or Fisher's exact test. There was no significant difference in the overall use of "access" antibiotics ( = 1.0) or first-line drugs ( = 0.4483) between M-PCR/P-AST and SUC. Nitrofurantoin ( = 0.0172) and metronidazole ( = 0.0309) were more frequently used with M-PCR/P-AST, while amoxicillin/clavulanate ( = 0.0008), cefuroxime ( = 0.0378), and ertapenem ( = 0.0378) were more frequently used with SUC. The use of M-PCR/P-AST to guide complicated UTI management was not associated with the increased use of non-first-line antibiotics, such as carbapenems, compared to SUC. Combined with the prior reported evidence of improved patient outcomes in this same set of patients, this test should be considered for utilization when managing complicated UTI cases.
我们旨在比较泌尿外科医疗服务提供者在对同一组患者使用联合多重聚合酶链反应(M-PCR)/混合抗生素敏感性试验(P-AST)诊断测试与标准尿培养(SUC)时的处方行为和临床经验,此前已有报道称M-PCR/P-AST可改善临床结局。我们开展了一项多中心、前瞻性观察性研究(临床试验注册号:NCT05091931),并获得了西方机构审查委员会(IRB)的批准(20214705)。成年受试者被分为M-PCR/P-AST组(n = 250)和SUC组(n = 135)。治疗细节由临床医生和受试者调查确定。使用卡方检验或费舍尔精确检验比较处方抗生素的差异。M-PCR/P-AST组和SUC组在“备用”抗生素的总体使用情况(p = 1.0)或一线药物的使用情况(p = 0.4483)方面没有显著差异。呋喃妥因(p = 0.0172)和甲硝唑(p = 0.0309)在M-PCR/P-AST组中使用更为频繁,而阿莫西林/克拉维酸(p = 0.0008)、头孢呋辛(p = 0.0378)和厄他培南(p = 0.0378)在SUC组中使用更为频繁。与SUC相比?使用M-PCR/P-AST指导复杂性尿路感染的管理与碳青霉烯类等非一线抗生素的使用增加无关。结合此前在同一组患者中报道的改善患者结局的证据,在管理复杂性尿路感染病例时应考虑使用该测试。